Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cells

• Published in: Blood cancer journal (New York) Vol. 14; no. 1; pp. 94 - 9
• Main Authors: D’Agostino, Mattia, Rota-Scalabrini, Delia, Belotti, Angelo, Bertamini, Luca, Arigoni, Maddalena, De Sabbata, Giovanni, Pietrantuono, Giuseppe, Pascarella, Anna, Tosi, Patrizia, Pisani, Francesco, Pescosta, Norbert, Ruggeri, Marina, Rogers, Jennifer, Olivero, Martina, Garzia, Mariagrazia, Galieni, Piero, Annibali, Ombretta, Monaco, Federico, Liberati, Anna Marina, Palmieri, Salvatore, Stefanoni, Paola, Zamagni, Elena, Bruno, Benedetto, Calogero, Raffaele Adolfo, Boccadoro, Mario, Musto, Pellegrino, Gay, Francesca
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 07.06.2024; Springer Nature B.V; Nature Publishing Group
• Subjects: 14/32; 38/91; 631/67/1990/804; 692/499; 692/699/1541/1990/804; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biomedical and Life Sciences; Biomedicine; Cancer Research; Chromosomes, Human, Pair 1 - genetics; Female; Gene Expression Regulation, Neoplastic; Hematology; Humans; Male; Medical prognosis; Middle Aged; Multiple myeloma; Multiple Myeloma - genetics; Multiple Myeloma - mortality; Multiple Myeloma - therapy; Oncology; Plasma Cells - metabolism; Plasma Cells - pathology; Prognosis; Transcriptome
• ISSN: 2044-5385; 2044-5385
• DOI: 10.1038/s41408-024-01075-x

Additional copies of chromosome 1 long arm (1q) are frequently found in multiple myeloma (MM) and predict high-risk disease. Available data suggest a different outcome and biology of patients with amplification (Amp1q, ≥4 copies of 1q) vs. gain (Gain1q, 3 copies of 1q) of 1q. We evaluated the impact of Amp1q/Gain1q on the outcome of newly diagnosed MM patients enrolled in the FORTE trial (NCT02203643). Among 400 patients with available 1q data, 52 (13%) had Amp1q and 129 (32%) Gain1q. After a median follow-up of 62 months, median progression-free survival (PFS) was 21.2 months in the Amp1q group, 54.9 months in Gain1q, and not reached (NR) in Normal 1q. PFS was significantly hampered by the presence of Amp1q (HR 3.34 vs. Normal 1q, P  < 0.0001; HR 1.99 vs. Gain1q, P  = 0.0008). Patients with Gain1q had also a significantly shorter PFS compared with Normal 1q (HR 1.68, P  = 0.0031). Concomitant poor prognostic factors or the failure to achieve MRD negativity predicted a median PFS < 12 months in Amp1q patients. Carfilzomib–lenalidomide–dexamethasone plus autologous stem cell transplantation treatment improved the adverse effect of Gain1q but not Amp1q. Transcriptomic data showed that additional 1q copies were associated with deregulation in apoptosis signaling, p38 MAPK signaling, and Myc-related genes.